LIR Life Sciences Corp
Paid advertisement on behalf of
LIR Life Sciences Corp
LIR Life Sciences Corp
LIR Life Sciences Corp. (CSE: SKNY | FSE: N790), headquartered in Vancouver, British Columbia, is a biotechnology company developing non-invasive drug delivery platforms for obesity treatment.
The company is advancing transdermal patches and alternative delivery systems designed to make GLP-1 and GIP-based therapies more accessible, affordable, and patient-friendly as alternatives to injectable treatments. With no FDA-approved transdermal GLP-1 formulations currently on the market, LIR is positioned in a white space within the rapidly expanding $156.7 billion global GLP-1 market.
The company recently filed a provisional patent application covering its needle-free delivery platform and has completed the design of comparative animal studies to validate its proprietary cell-penetrating peptide technology.
The Obesity Treatment Revolution
The global obesity crisis is reaching an unprecedented scale. The World Obesity Federation estimates that by 2035, nearly four billion people will be affected by obesity, representing one quarter of the global population.
U.S. spending on GLP-1 therapies reached $71.7 billion in 2023, with approximately 20 million Americans currently using these medications at an average annual cost of $12,000 per year.
Despite this explosive growth, current injectable treatments create significant barriers. Needle aversion, injection-site discomfort, refrigeration requirements, and high costs limit access—particularly in emerging markets where obesity rates are climbing rapidly.
LIR’s research targets this accessibility gap with transdermal and sublingual delivery methods that leverage proven GLP-1 and GIP compounds in novel formulations.
Proprietary Technology Platform
LIR’s core innovation is a cell-penetrating peptide–enhanced delivery system designed to transport GLP-1 and GIP-based therapies through the skin barrier and into systemic circulation at therapeutic levels.
The company filed a provisional patent application in December 2025 covering transdermal formats—including patches, creams, and gels—as well as sublingual administration methods.
This platform-based approach is strategic. Rather than developing a single product, LIR is building technology intended to be compatible with multiple existing and future GLP-1 and GIP-based medicines. This approach may support combination products and enable multiple commercialization pathways.
The company has completed the design of a controlled comparative animal study evaluating how effectively its transdermal formulations enable therapeutic molecules to permeate the skin and support glucose control relative to traditional injectable administration.
Investor Highlights
How To Invest
LIR Life Sciences trades on the Canadian Securities Exchange (CSE: SKNY) and the Frankfurt Stock Exchange (FSE: N790, WKN: A41QA9). To invest, click below to be redirected to brokerage platforms or search for SKNY on your preferred trading platform.
Disclosure
The Sunrise Investor is a media platform owned by Fairfax Partners Inc. This article is part of a paid media engagement. Fairfax Partners Inc. has received compensation from the company mentioned for editorial coverage.
Content is for informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities. Information is based on publicly available sources believed to be accurate at the time of publication.
Readers should conduct their own due diligence and consult licensed financial professionals before making investment decisions. Public and early-stage investments involve risk, including potential loss of capital.
This article complies with Section 52(2) of the Canadian Competition Act, SEC Rules 17(b) and 10b-5 (U.S.), UK FCA MAR, and EU ESMA MAR. Any forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
By reading this article, you acknowledge and accept these terms